Jak3 Antibody

What are the optimal conditions for Western blot detection of JAK3 using antibodies?

For effective Western blot detection of JAK3 (approximately 120 kDa), reducing conditions are recommended with immunoblot buffer systems optimized for phosphoproteins. Based on validated protocols, PVDF membranes probed with 2 µg/mL of anti-JAK3 monoclonal antibody followed by HRP-conjugated secondary antibody provide specific detection in human cell lines such as TF-1 erythroleukemic cells . To increase sensitivity when detecting endogenous JAK3, consider:

• Using a lysis buffer containing phosphatase inhibitors to preserve phosphorylation states

• Running gels at lower voltage (80-100V) to improve resolution

• Extending primary antibody incubation to overnight at 4°C

• Implementing enhanced chemiluminescence detection systems

How should I validate JAK3 antibody specificity in my experimental system?

Antibody validation should include multiple complementary approaches:

• Positive and negative controls: Compare JAK3 detection in cell lines known to express high levels (TF-1, lymphoid cells) versus those with minimal expression

• Knockout/knockdown validation: Use JAK3 knockout cells or JAK3 siRNA knockdown samples as negative controls

• Peptide competition: Pre-incubate antibody with the immunizing peptide (Gly46-Thr209 for the antibody in result #6) to confirm specific epitope recognition

• Cross-reactivity assessment: Test reactivity against other JAK family members (JAK1, JAK2, TYK2) to ensure specificity

• Antibody performance in multiple applications: Validate across Western blot, immunoprecipitation, and immunofluorescence applications

What are the recommended storage conditions to maintain JAK3 antibody integrity?

Based on established protocols for maintaining antibody activity:

• Store lyophilized antibodies at -20°C to -70°C for up to 12 months

• After reconstitution, store at 2-8°C under sterile conditions for up to 1 month

• For long-term storage after reconstitution, aliquot and store at -20°C to -70°C for up to 6 months

• Avoid repeated freeze-thaw cycles by creating single-use aliquots

• Use a manual defrost freezer rather than auto-defrost to prevent temperature fluctuations

How can I detect the interaction between JAK3 and the γc chain using antibodies?

To study JAK3-γc interactions, co-immunoprecipitation (Co-IP) techniques have been validated in multiple systems:

• Direct Co-IP approach:

  • Transfect cells with JAK3 and γc or use cells endogenously expressing both proteins

  • Immunoprecipitate with anti-γc antibodies (or chimeric receptors like Tacγc)

  • Perform Western blot with anti-JAK3 antibodies

  • Include appropriate controls (JAK1, JAK2) to demonstrate specificity

• Competition assay for binding specificity:

  • Co-express full-length JAK3 with JAK3 deletion mutants (particularly J3(StuI) containing JH7-6 domains)

  • Immunoprecipitate the receptor and probe for competition between full-length and truncated JAK3

This methodology has conclusively demonstrated that the N-terminal JH7-6 domains of JAK3 are necessary and sufficient for γc binding .

How can I use antibodies to investigate JAK3's role in TLR-mediated immune responses?

To study JAK3's function in TLR signaling pathways:

• Phosphorylation analysis workflow:

  • Stimulate cells (monocytes, macrophages) with TLR ligands (e.g., LPS for TLR4)

  • Collect lysates at multiple time points (0-120 min)

  • Perform Western blot using phospho-specific antibodies targeting:

    • Phosphorylated JAK3

    • Downstream effectors: mTORC1, Akt, GSK3β, CREB

  • Compare phosphorylation patterns between wild-type and JAK3-inhibited conditions

• Validation experiments:

  • Conduct parallel experiments with JAK3 inhibitors (T-1377, WHIP-154)

  • Use JAK3 siRNA knockdown

  • Include JAK3 knockout cells as controls

  • Measure cytokine production (IL-12, TNF-α, IL-6, IL-10) via ELISA

This approach has revealed that JAK3 inhibition enhances TLR-mediated production of pro-inflammatory cytokines while suppressing IL-10 production, suggesting JAK3 has a regulatory role in innate immune responses .

What methods can distinguish between JAK3-dependent and JAK3-independent cytokine signaling?

To differentiate JAK3-dependent from JAK3-independent pathways:

• Comparative signaling analysis:

  • Treat cells with cytokines that signal through:

    • γc-dependent receptors (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21)

    • γc-independent receptors (IL-6, IFN-γ)

  • Use phospho-specific antibodies to detect activation of:

    • JAK3 (γc-dependent pathways)

    • JAK1/JAK2/TYK2 (can be γc-independent)

    • STAT proteins (STAT5 for JAK3-dependent; others for independent pathways)

• Selective inhibition strategy:

  • Apply highly selective JAK3 inhibitors (e.g., Z583, IC50 of 0.1 nM with >4500-fold selectivity)

  • Monitor differential effects on γc cytokine signaling versus other cytokine pathways

  • Use phospho-flow cytometry with JAK3 and STAT antibodies for single-cell resolution

This approach has demonstrated that selective JAK3 inhibition specifically blocks γc cytokine signaling while sparing other JAK-dependent pathways .

How can I use antibodies to evaluate JAK3 inhibitor selectivity in cellular assays?

To assess JAK3 inhibitor selectivity:

• Multi-parameter evaluation system:

  • Stimulate cells with γc cytokines (IL-2, IL-4, IL-15)

  • Pre-treat with putative JAK3-selective inhibitors at multiple concentrations

  • Prepare parallel samples for:

    • Immunoblotting: phospho-JAK3, phospho-JAK1/2, phospho-STAT5/3

    • Flow cytometry: intracellular phospho-protein detection

    • ELISA: downstream cytokine production

• Specificity controls:

  • Include JAK1/JAK2-dependent cytokine stimulation (e.g., IL-6, IFN-γ)

  • Compare selective inhibition profiles between JAK family members

  • Use kinase assays with recombinant proteins to confirm biochemical selectivity

This methodology has been used to characterize highly selective JAK3 inhibitors like Z583, which demonstrated complete inhibition of γc cytokine signaling while sparing other JAK-dependent pathways .

What approaches can resolve antibody cross-reactivity issues between JAK family members?

To address potential cross-reactivity between highly homologous JAK family proteins:

• Epitope mapping strategy:

  • Select antibodies targeting non-conserved regions between JAK family members

  • For JAK3, focus on antibodies recognizing the N-terminal region (JH7-JH6 domains) which show greatest sequence divergence

  • Validate using recombinant JAK proteins and JAK-specific knockout cells

• Cross-reactivity elimination techniques:

  • Pre-absorb antibodies with recombinant JAK1/JAK2/TYK2 proteins

  • Use competition assays with peptides derived from homologous regions

  • Implement stringent washing conditions to remove low-affinity binding

  • Consider using JAK3-deficient cells (from SCID patients) as negative controls

• Chimeric protein approach:

  • Utilize JAK chimeric proteins (e.g., J3J2) containing domains from different JAK proteins

  • Test antibody reactivity against these chimeras to pinpoint cross-reactive epitopes

How should I design experiments to study low-dose versus high-dose JAK3 inhibition in T-cell responses?

Recent research has revealed dose-dependent paradoxical effects of JAK3 inhibition on T-cell function. To properly investigate this phenomenon:

• Dose optimization protocol:

  • Establish a full dose-response curve (0.1 nM to 10 μM)

  • Test both pulsed high-dose and chronic low-dose administration:

    • Pulsed: Higher concentrations applied intermittently

    • Chronic: Lower concentrations maintained continuously

  • Evaluate T-cell parameters including:

    • Proliferation (CFSE dilution)

    • Cytokine production (intracellular staining)

    • Exhaustion markers (PD-1, TIM-3, LAG-3)

    • STAT5 phosphorylation status

• In vivo validation design:

  • Compare administration routes and schedules:

    • High-dose intermittent versus low-dose continuous

    • Monitor tumor growth kinetics in cancer models

    • Assess combination with immunotherapies (vaccines, checkpoint inhibitors)

This methodological approach has demonstrated that while high-dose JAK3 inhibition suppresses T-cell function, low-dose chronic administration actually improves antitumor T-cell immunity and decreases tumor load in mouse models .

What experimental parameters should be considered when using JAK3 antibodies in conjunction with JAK3 inhibitors?

When combining JAK3 antibodies with inhibitors:

• Sequential analysis workflow:

  • Pre-treat cells with JAK3 inhibitor (e.g., Z583, T-1377)

  • Stimulate with appropriate cytokines (IL-2, IL-4)

  • Fix cells at multiple timepoints (5-60 minutes)

  • Perform immunoblotting or flow cytometry with:

    • Total JAK3 antibodies

    • Phospho-specific JAK3 antibodies

    • Antibodies to downstream signaling molecules

• Critical experimental controls:

  • Include vehicle-only treated samples

  • Test structurally distinct JAK3 inhibitors to rule out off-target effects

  • Evaluate JAK3 protein levels to ensure inhibition is not affecting expression

  • Monitor for inhibitor-induced JAK3 conformational changes that might affect antibody binding

  • Consider epitope masking by inhibitor binding

This approach has been used to demonstrate that JAK3 inhibitors affect downstream signaling cascades including PI3K-Akt-mTORC1-GSK3β pathway .

How can I use JAK3 antibodies to investigate SCID-associated JAK3 mutations?

To study JAK3 mutations associated with SCID:

• Mutation analysis pipeline:

  • Generate expression constructs with patient-derived JAK3 mutations

  • Transfect into relevant cell systems (e.g., JAK3-deficient cell lines)

  • Assess:

    • Total JAK3 protein expression (Western blot)

    • Subcellular localization (immunofluorescence microscopy)

    • γc binding capacity (co-immunoprecipitation)

    • Kinase activity (phospho-specific antibodies)

• Trafficking and localization assessment:

  • Perform subcellular fractionation with membrane, cytosolic, and nuclear fractions

  • Use confocal microscopy with JAK3 and γc antibodies

  • Compare wild-type and mutant trafficking patterns

This approach has revealed that many patient-derived JAK3 mutations abolish normal JAK3/γc membrane localization, contributing to SCID pathogenesis through aberrant trafficking even when protein is expressed .

What methodologies can help investigate JAK3's role in rheumatoid arthritis using antibodies?

To investigate JAK3 in rheumatoid arthritis models:

• Translational research workflow:

  • Analyze synovial tissue samples from RA patients versus controls:

    • JAK3 expression levels (immunohistochemistry, Western blot)

    • JAK3 activation status (phospho-specific antibodies)

    • Co-localization with inflammatory cell markers

• Animal model assessment:

  • In collagen-induced arthritis (CIA) models:

    • Monitor JAK3 expression and phosphorylation during disease progression

    • Evaluate effects of JAK3 inhibitors (Z583) on:

      • Clinical scores

      • Histopathology

      • Inflammatory cytokine profiles

    • Perform immunohistochemical analysis with JAK3 antibodies

    • Isolate and analyze immune cell populations from joints

These approaches have demonstrated that selective JAK3 inhibition effectively blocks inflammatory responses in RA models while sparing hematopoiesis, suggesting therapeutic potential .

How can I address inconsistent JAK3 detection in primary immune cells?

When facing variable JAK3 detection in primary cells:

• Optimization strategy:

  • Adjust cell isolation protocols to minimize activation:

    • Use cold buffers and process quickly

    • Add phosphatase inhibitors immediately

    • Consider fixing cells before processing

  • Test multiple antibody clones recognizing different epitopes

  • Modify lysis conditions (RIPA vs. NP-40 vs. digitonin-based buffers)

  • For flow cytometry, optimize fixation and permeabilization protocols

• Validation checkpoints:

  • Confirm JAK3 expression levels in your cell type (qPCR)

  • Use positive control cell lines alongside primary cells

  • Consider cell activation state (resting vs. activated T cells)

  • Account for JAK3 degradation during extended processing

How can I reconcile contradictory findings about JAK3's role in TLR-mediated responses?

To address contradictory results regarding JAK3 in TLR signaling:

• Systematic troubleshooting approach:

  • Verify inhibitor specificity:

    • Use concentrations that minimize cross-reactivity with other JAKs

    • Compare multiple structurally distinct JAK3 inhibitors

    • Confirm findings with genetic approaches (siRNA, CRISPR)

  • Consider timing and context:

    • Evaluate acute versus chronic JAK3 inhibition

    • Assess different cell types (monocytes vs. macrophages vs. DCs)

    • Examine species differences (human vs. mouse systems)

• Combinatorial analysis:

  • Implement multiple complementary methods:

    • Pharmacological inhibition (T-1377, WHIP-154)

    • siRNA knockdown

    • JAK3 knockout cells/animals

  • Measure outcomes at multiple levels:

    • Signaling pathway activation

    • Transcriptional responses

    • Protein secretion

    • Functional consequences

This approach has helped clarify that JAK3 inhibition enhances TLR-mediated pro-inflammatory cytokine production while suppressing IL-10, reconciling seemingly contradictory findings in different experimental systems .

What strategies can differentiate JAK3 from other JAK family members when antibodies show cross-reactivity?

When antibody cross-reactivity is problematic:

• Differential expression approach:

  • Utilize cell lines with known JAK expression profiles:

    • JAK3: predominantly in hematopoietic cells

    • JAK1/JAK2: more ubiquitously expressed

  • Perform parallel knockdown experiments targeting each JAK

  • Use tissue samples from JAK-deficient mice as controls

• Functional discrimination strategy:

  • Stimulate with cytokines that activate specific JAK combinations:

    • IL-2, IL-4, IL-15: JAK3/JAK1

    • IFN-γ: JAK1/JAK2

    • IL-6: JAK1/JAK2/TYK2

  • Utilize highly selective inhibitors (Z583 for JAK3)

  • Perform immunodepletion with verified specific antibodies before analysis

• Molecular weight distinction:

  • Optimize gel resolution to separate JAK family members:

    • JAK1: ~130-135 kDa

    • JAK2: ~125-130 kDa

    • JAK3: ~120-125 kDa

    • TYK2: ~130-140 kDa